Observational study on CAR-T therapy for lymphoma in Italy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to monitor the feasibility, efficacy, and toxicity of CAR-T therapy for various types of lymphoma in a real-life setting. Participants will consent to the collection of their clinical data and may take part in an optional biological study to evaluate biomarkers related to toxicity and treatment response. The study will assess disease response using PET and CT scans according to Lugano criteria, and will track patient outcomes over a three-year period. It will also compare survival outcomes between treated patients and those who were eligible but did not receive treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with diagnosis of DLCBL, PMBCL, MCL and FL eligible for CAR-T treatment with commercialy available products in Italy.

Exclusion Criteria:

* Not applicable

Where it's running

• Fondazione IRCCS Istituto Nazionale Tumori
  Milan, Italy Recruiting

Study contacts

• Study coordinator: Paolo Corradini, Professor
• Email: paolo.corradini@istitutotumori.mi.it
• Phone: +39 02 2390 2950

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using CD79b-19 CAR T cells to treat Non-Hodgkin Lymphoma

  This study is testing a new treatment using modified immune cells to see if it can help people with relapsed or hard-to-treat Non-Hodgkin Lymphoma.

  Recruiting Phase 1 Massachusetts General Hospital · Boston, Massachusetts · NCT06026319

• Evaluating vaccine responses in patients with multiple myeloma and non-Hodgkin lymphoma after CAR-T treatment

  This study tests how well vaccines work in people with multiple myeloma and non-Hodgkin lymphoma after they have received CAR-T treatment.

  Recruiting OHSU Knight Cancer Institute · Portland, Oregon · NCT06784167

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

• Gene therapy for certain blood cancers

  This study is testing a new gene therapy called VNX-101 to see if it can help people with certain types of blood cancers that haven't responded to other treatments.

  Recruiting at 11 sites Phase 1/2 Vironexis Biotherapeutics Inc. · Duarte, California and 10 other locations · NCT06533579

• Using LV20.19 CAR T-Cells with Pirtobrutinib for B-cell Malignancies

  This study is testing a new treatment combining LV20.19 CAR T-cells with pirtobrutinib to see if it helps adults with tough-to-treat B-cell cancers feel better.

  Recruiting Phase 1 Medical College of Wisconsin · Milwaukee, Wisconsin · NCT05990465

• Combining pembrolizumab with CAR T-cell therapy for recurrent primary mediastinal large B-cell lymphoma

  This study is testing if adding pembrolizumab to CAR T-cell therapy can help people with recurrent primary mediastinal large B-cell lymphoma feel better and live longer.

  Recruiting at 2 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT05934448

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.